Evidence map›Paper›PMID 31520321›Full record

ArticleInvestigational new drugs2020

Synthesis and cellular effects of novel 1,3,5-triazine derivatives in DLD and Ht-29 human colon cancer cell lines.

Agnieszka Wróbel, Beata Kolesińska, Justyna Frączyk, Zbigniew J Kamiński, Anna Tankiewicz-Kwedlo, Justyna Hermanowicz, Robert Czarnomysy, Dawid Maliszewski, Danuta Drozdowska

Open access · hybridAbstract read
In one paragraph

Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. mPEG-Polymers · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Current drug discovery technologies · 2024
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Agnieszka WróbelDepartment of Organic Chemistry, Medical University of Bialystok, Białystok, Poland.
Beata KolesińskaInstitute of Organic Chemistry, Lodz University of Technology, Lodz, Poland.
Justyna FrączykInstitute of Organic Chemistry, Lodz University of Technology, Lodz, Poland.
Zbigniew J KamińskiInstitute of Organic Chemistry, Lodz University of Technology, Lodz, Poland.
Anna Tankiewicz-KwedloDepartment of Monitored Pharmacotherapy, Medical University of Bialystok, Białystok, Poland.
Justyna HermanowiczDepartment of Clinical Pharmacy, Medical University of Bialystok, Bialystok, Poland.
Robert CzarnomysyDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Bialystok, Poland.
Dawid MaliszewskiDepartment of Organic Chemistry, Medical University of Bialystok, Białystok, Poland.
Danuta DrozdowskaDepartment of Organic Chemistry, Medical University of Bialystok, Białystok, Poland. danuta.drozdowska@umb.edu.pl.ORCID 0000-0002-3479-0480
Medical University of Białystok · PLLodz University of Technology · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study provides new information on the cellular effects of 1,3,5-triazine nitrogen mustards with different peptide groups in DLD and Ht-29 human colon cancer cell lines. A novel series of 2,4,6-trisubstituted 1,3,5-triazine derivatives bearing 2-chloroethyl and oligopeptide moieties was designed and synthesized. The most cytotoxic derivative was triazine with an Ala-Ala-OMe substituent on the ring (compound 7b). This compound induced time- and dose-dependent cytotoxicity in the DLD-1 and HT-29 colon cancer cell lines. The triazine derivative furthermore induced apoptosis through intracellular signaling pathway attenuation. Compound 7b may be a candidate for further evaluation as a chemotherapeutic agent against colorectal cancer.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell ProliferationColonic NeoplasmsHumansMembrane Potential, MitochondrialProto-Oncogene Proteins c-bcl-2TriazinesAntineoplastic AgentsBCL2 protein, humanProto-Oncogene Proteins c-bcl-2TriazinesApoptosisColon cancerDrug designHybrid anticancer drugsNitrogen mustardsTriazine derivatives

Identifiers

PMID31520321
PMCPMC7340680
OpenAlexW2972980454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.